MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company has a licensing and collaboration agreement with United Therapeutics Corporation for the development and commercialization of a dry powder formulation of treprostinil used for the treatment of pulmonary arterial hypertension.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone818-661-5000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$27.86 million
Profitability
Miscellaneous
Employees225
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
MannKind (NASDAQ:MNKD) Frequently Asked Questions
What is MannKind's stock symbol?
MannKind trades on the NASDAQ under the ticker symbol "MNKD."
How were MannKind's earnings last quarter?
MannKind Co. (NASDAQ:MNKD) issued its quarterly earnings data on Wednesday, August, 7th. The biopharmaceutical company reported ($0.07) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.07). The biopharmaceutical company earned $15 million during the quarter, compared to analyst estimates of $14.83 million. During the same quarter in the prior year, the firm posted ($0.16) earnings per share. View MannKind's Earnings History.
When is MannKind's next earnings date?
What price target have analysts set for MNKD?
4 brokers have issued 12 month price objectives for MannKind's shares. Their predictions range from $3.00 to $3.00. On average, they expect MannKind's share price to reach $3.00 in the next year. This suggests a possible upside of 185.7% from the stock's current price. View Analyst Price Targets for MannKind.
What is the consensus analysts' recommendation for MannKind?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MannKind in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MannKind.
Has MannKind been receiving favorable news coverage?
Media stories about MNKD stock have trended positive this week, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. MannKind earned a daily sentiment score of 2.5 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 6.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the company's share price in the immediate future. View News Stories for MannKind.
Who are some of MannKind's key competitors?
Some companies that are related to MannKind include Homology Medicines (FIXX), ZIOPHARM Oncology (ZIOP), Amneal Pharmaceuticals (AMRX), Akero Therapeutics (AKRO), Principia Biopharma (PRNB), ANI Pharmaceuticals (ANIP), Arvinas (ARVN), Eagle Pharmaceuticals (EGRX), Vanda Pharmaceuticals (VNDA), OrganiGram (OGI), Alder Biopharmaceuticals (ALDR), CannTrust (CNTTF), Kura Oncology (KURA), Cytokinetics (CYTK) and Wave Life Sciences (WVE).
What other stocks do shareholders of MannKind own?
Who are MannKind's key executives?
MannKind's management team includes the folowing people:
- Dr. Michael E. Castagna, CEO & Director (Age 42)
- Mr. Steven B. Binder, Chief Financial Officer (Age 56)
- Mr. Joseph Kocinsky, Chief Technology Officer (Age 55)
- Ms. Rosabel Realica Alinaya, Sr. VP of Investor Relations & Treasury (Age 58)
- Dr. David B. Thomson, Corp. VP, Gen. Counsel & Sec. (Age 52)
Who are MannKind's major shareholders?
MannKind's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.53%), Vanguard Group Inc. (5.18%), Raging Capital Management LLC (1.61%), D. E. Shaw & Co. Inc. (1.09%), Northern Trust Corp (1.03%) and Scopia Capital Management LP (0.49%). Company insiders that own MannKind stock include Kent Kresa, Michael Castagna, Patrick Mccauley, Steven B Binder and Stuart A Tross. View Institutional Ownership Trends for MannKind.
Which major investors are selling MannKind stock?
Which major investors are buying MannKind stock?
MNKD stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Scopia Capital Management LP, Vanguard Group Inc., Alps Advisors Inc., Chicago Equity Partners LLC, Wells Fargo & Company MN, A.R.T. Advisors LLC and Raging Capital Management LLC. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Michael Castagna, Patrick Mccauley, Steven B Binder and Stuart A Tross. View Insider Buying and Selling for MannKind.
How do I buy shares of MannKind?
Shares of MNKD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MannKind's stock price today?
One share of MNKD stock can currently be purchased for approximately $1.05.
How big of a company is MannKind?
MannKind has a market capitalization of $199.10 million and generates $27.86 million in revenue each year. The biopharmaceutical company earns $-86,970,000.00 in net income (profit) each year or ($0.59) on an earnings per share basis. MannKind employs 225 workers across the globe.View Additional Information About MannKind.
What is MannKind's official website?
How can I contact MannKind?
MannKind's mailing address is 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA, 91362. The biopharmaceutical company can be reached via phone at 818-661-5000 or via email at [email protected]
MarketBeat Community Rating for MannKind (NASDAQ MNKD)
MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe MNKD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MNKD will underperform the S&P 500 over the long term. You may vote once every thirty days.
